Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Trials conducted between 2001 and 2007 demonstrated statistically significant reductions in body fat, although the larger Phase IIb OPTIONS trial did not replicate these findings at sufficient magnitude for regulatory approval, and formal development was discontinued in 2007
Not all protocols include this tier
Clinical trials have explored the safety profile of AOD and reported few adverse effects, such as insulin resistance or unwanted muscle growth, which are typically associated with traditional GH therapies (2)
Medicaid: State Medicaid programs have their own fee schedules and covered diagnosis requirements
US$ 20.48
US$ 23.51
US$ 24.09
US$ 29.02
US$ 23.19
